Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Hanne Skjerven Bersvendsen"'
Autor:
Cecilie E. Kiserud, Hanne Skjerven Bersvendsen, Unn-Merete Fagerli, Floortje Mols, Knut B. Smeland, Alexander Fosså, Siri A Eikeland
Publikováno v:
Acta Oncologica, 60(7), 911-920. TAYLOR & FRANCIS LTD
Acta Oncologica
Acta Oncologica
BackgroundChemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of Hodgkin’s lymphoma (HL) treatment. We aimed to describe the prevalence of CIPN associated symptoms in long-term HL survivors compared to controls, and det
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f3b230270f6ccd2bec38fb992233091
https://doi.org/10.1080/0284186X.2021.1917776
https://doi.org/10.1080/0284186X.2021.1917776
Autor:
Cecilie E. Kiserud, Hanne Skjerven Bersvendsen, Hege Sagstuen Haugnes, Tom Wilsgaard, Harald Holte, Unn-Merete Fagerli, Øystein Fluge, Alv A. Dahl, Knut B. Smeland
Publikováno v:
Bone Marrow Transplantation. 56:968-970
Sexual function in female lymphoma survivors after high-dose therapy with autologous stem-cell transplantation (auto-SCT) is largely unstudied. Female lymphoma survivors treated with auto-SCT in Norway 1987-2008 were eligible participants (n = 157).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::01293ab87976103ea96690012df75a2d
https://doi.org/10.1038/s41409-020-01098-5
https://doi.org/10.1038/s41409-020-01098-5
Autor:
Unn-Merete Fagerli, Cecilie E. Kiserud, Mette Seland, Alv A. Dahl, Tom Wilsgaard, Hege Sagstuen Haugnes, Øystein Fluge, Hanne Skjerven Bersvendsen, Harald Holte, Knut B. Smeland
Publikováno v:
Bone Marrow Transplantation. 55:891-905
Reduced sexual function may have negative implications on health related quality of life among lymphoma survivors. A national cross-sectional study among long-term lymphoma survivors after high-dose therapy with autologous stem-cell transplantation a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0708096af93453285181bc28aa94605c
https://doi.org/10.1038/s41409-019-0745-4
https://doi.org/10.1038/s41409-019-0745-4
Autor:
Renate Galleberg, Unn-Merete Fagerli, Harald Holte, Alexander Fosså, Knut B. Smeland, Hanne Skjerven Bersvendsen
Publikováno v:
Acta Oncologica. 59:101-105
About 20% of patients with classical Hodgkin lymphoma (cHL) progress or relapse after first-line therapy [1,2]. High-dose therapy with autologous stem cell transplantation (ASCT) is the standard of...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48f516ca294d9ce998caa21b5dd1ad7b
https://doi.org/10.1080/0284186x.2019.1652765
https://doi.org/10.1080/0284186x.2019.1652765
Autor:
Simona Berardi Vilei, Andreas Lohri, Mario Bargetzi, Ulrich Mey, Micaela Hernberg, Stefan Dirnhofer, Thilo Zander, Ann-Sofie Johansson, Peter de Nully Brown, Walter Mingrone, Eva Kimby, Bjørn Østenstad, Urban Novak, Daniel Rauch, Björn E. Wahlin, Fatime Krasniqi, Felicitas Hitz, Emanuele Zucca, Michele Ghielmini, Stefanie Hayoz, Hans Hagberg, Hanne Skjerven Bersvendsen, Hanne Hawle, Andrés J.M. Ferreri, Anna Vanazzi, Stephanie Rondeau
Publikováno v:
Blood. 134:353-362
The SAKK 35/10 phase 2 trial, developed by the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group, compared the activity of rituximab vs rituximab plus lenalidomide in untreated follicular lymphoma patients in need of systemic the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0fd9e89e0f0247df56153468353844f
https://doi.org/10.1182/blood-2018-10-879643
https://doi.org/10.1182/blood-2018-10-879643
Autor:
Cecilie E. Kiserud, Harald Holte, Knut B. Smeland, Alexander Fosså, Hans Christian Dalsbotten Aass, Nils Bolstad, Klaus Murbraech, Hanne Skjerven Bersvendsen, Jo S Stenehjem, Kristin V. Reinertsen, Øystein Fluge, Jon Håvard Loge, May-Brith Lund, Trude Aspelin, Ragnhild Sørum Falk, Unn-Merete Fagerli
Publikováno v:
Bone Marrow Transplantation
© 2018. This is the authors' accepted and refereed manuscript to the chapter. Locked until 27.3.2019 due to copyright restrictions. The final authenticated version is available online at: http://dx.doi.org/10.1038/s41409-018-0342-y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41c7bee52e433af13895354c3c5d9066
https://doi.org/10.1038/s41409-018-0342-y
https://doi.org/10.1038/s41409-018-0342-y
Autor:
Øystein Fluge, Hege Sagstuen Haugnes, Tom Wilsgaard, Unn-Merete Fagerli, Cecilie E. Kiserud, Knut B. Smeland, Hanne Skjerven Bersvendsen, Harald Holte
Publikováno v:
Acta Oncologica
This is an Accepted Manuscript of an article published by Taylor & Francis in Acta Oncologica on 30 Jan 2019, available online: http://www.tandfonline.com/ https://doi.org/10.1080/0284186X.2018.1558370. Introduction: High-dose therapy with autologous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45b9d6142a50c1d51d89afada81636a3
https://hdl.handle.net/10037/17431
https://hdl.handle.net/10037/17431
Autor:
Unn-Merete Fagerli, Alexander Fosså, Cecilie E. Kiserud, Øystein Fluge, Knut B. Smeland, Alv A. Dahl, Victoria Charlotte Simensen, Hanne Skjerven Bersvendsen
urpose: Lymphoma survivors after high dose therapy with autologous stem cell therapy (HD-ASCT) are at high risk for late adverse effects (AEs). Information patients receive and collect throughout their cancer trajectory about diagnosis, treatment sch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f0e6792ed0ce8d12e82e1f44f1a50a7
http://hdl.handle.net/10852/75137
http://hdl.handle.net/10852/75137
Autor:
Cecilie E. Kiserud, Alexander Fosså, Hanne Skjerven Bersvendsen, Knut B. Smeland, U-M. Fagerli, Floortje Mols, S.A. Eikeland
Publikováno v:
Annals of Oncology. 31:S1065
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89bdbc9687d85229f589cea7e7bad125
https://doi.org/10.1016/j.annonc.2020.08.1512
https://doi.org/10.1016/j.annonc.2020.08.1512
Autor:
Cecilie E. Kiserud, Unn-Merete Fagerli, Hanne Skjerven Bersvendsen, Hege Sagstuen Haugnes, Harald Holte, Øystein Fluge, Knut B. Smeland
Publikováno v:
Hematological Oncology. 37:544-545
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::882c8964f510aa5831031a1d1cc311da
https://doi.org/10.1002/hon.231_2631
https://doi.org/10.1002/hon.231_2631